Category Archives: Diagnostics

Ultra-thin meta lens enables full colour imaging

Wax Selection – Leaders in Pharma, Biotech & MedTech Recruitment

A meta lens developed by researchers at only one micron thick, has the ability to perform better than any compound lens currently available.

The first flat lens capable of correctly focusing a large range of colours of any polarisation to the same focal spot without the need for any additional elements has been developed.

Researchers at Colombia University School of Engineering and Applied Science developed the lens which is only a micron thick, but offers the performance of the best compound lens systems.

Associate Professor Nanfang Yu led the study and said: “The beauty of our flat lens is that by using meta-atoms of complex shapes, it not only provides the correct distribution of delay for a single colour of light but also for a continuous spectrum of light.

“And because they are so thin, they have the potential to drastically reduce the size and weight of any optical instrument or device used for imaging, such as cameras, microscopes, telescopes, and even our eyeglasses. Think of a pair of eyeglasses with a thickness thinner than a sheet of paper, smartphone cameras that do not bulge out, thin patches of imaging and sensing systems for driverless cars and drones, and miniaturised tools for medical imaging applications.”

The meta-lenses used standard 2D planar fabrication techniques similar to those used for fabricating computer chips. The researchers mention that mass manufacturing these meta-lenses should be simple as they are only one layer of nanostructure, and there is no need to go through the expensive and time-consuming grinding and polishing process.

“The production of our flat lenses can be massively parallelised, yielding large quantities of high performance and cheap lenses,” noted Sajan Shrestha, a doctoral student in Yu’s group who was co-lead author of the study. “We can therefore send our lens designs to semiconductor foundries for mass production and benefit from economies of scale inherent in the industry.”

“Our design algorithm exhausts all degrees of freedom in sculpting an interface into a binary pattern, and, as a result, our flat lenses are able to reach performance approaching the theoretic limit that a single nanostructured interface can possibly achieve,” Adam Overvig, the study’s other co-lead author and also a doctoral student with Yu, said.

“In fact, we’ve demonstrated a few flat lenses with the best theoretically possible combined traits: for a given meta-lens diameter, we have achieved the tightest focal spot over the largest wavelength range.”

The study was published by Nature’s Light: Science and Applications.

SOURCE: www.europeanpharmaceuticalreview.com/news/79753/meta-lens-full-imaging

Novo Nordisk to launch connected insulin pens in early 2019

Wax Selection – Leaders in Pharma, Biotech & MedTech Recruitment

Danish healthcare firm Novo Nordisk has unveiled plans to introduce new durable, connected insulin pens in early 2019.

The new NovoPen 6 and NovoPen Echo Plus connected insulin pens will replace the NovoPen 5 and NovoPen Echo insulin pens.

Novo Nordisk will commence the launch of new connected insulin pens in the first quarter of 2019. They are expected to be available in more than 50 countries.

The company expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019.

Novo Nordisk commercial strategy and corporate affairs executive vice president said: “Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes.

“We firmly believe that this will help more people realise the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals.”

In parallel, the company has also entered into new partnership agreements with major diabetes technology firms such as Dexcom, Glooko and Roche to enable future integration of its connected pens with various digital health solutions.

As part of the deal with Roche, the partnership will incorporate insulin dosage information from Novo Nordisk’s connected pen technology into Roche’s open ecosystem, enabling to communicate with its digital diabetes management solutions such as mySugr.

The firm will also incorporate data from connected pen devices with its partners’ diabetes management solutions such as continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).

Novo Nordisk will incorporate insulin dosing data with Dexcom CGM data in the coming years.

Roche diabetes care global head Marcel Gmuender said: “We believe in the tremendous benefits integrated digital diabetes management solutions can bring to people with diabetes, caregivers and healthcare systems as part of an open ecosystem and are excited to partner with Novo Nordisk to further drive innovation in this area.”

With marketing activities in more than 170 countries, Novo Nordisk is engaged in providing treatment solutions for obesity, haemophilia, growth disorders and other serious chronic diseases.

SOURCE: www.compelo.com/medical-devices/news

Ipsen appoints two leading R&D experts in bid to strengthen oncology arm

Wax Selection – Leaders in Pharma, Biotech & MedTech Recruitment

French pharma firm Ipsen has announced the appointment of Dr. Yan Moore as Senior Vice President, Head of Oncology Therapeutic Area and Dr. Alexander “Sandy” McEwan, as Vice President, Head of Radiopharmaceuticals.

It is hoped that the move, which has seen the company take on two leading oncology specialists within a month of each other, will strengthen the company’s oncology arm.

Alexandre Lebeaut, Executive Vice President R&D and Chief Scientific Officer, Ipsen, commented: “I am thrilled to welcome Yan and Sandy as talented leaders who will assume pivotal roles in the next phase of our R&D transformation, and whose unique goal is to accelerate the development and deliver innovative therapeutic solutions to cancer patients.”

While Tel Aviv University graduate Dr Moore’s appointment with the Paris-headquartered company is effective immediately, Dr McEwan will join Ipsen on November 1st. Both R&D leaders will report to Dr. Alexandre Lebeaut, Executive Vice-President R&D and Chief Scientific Officer.

Dr Moore brings with him a wealth of experience from large multinationals including Bristol-Myers Squibb. Sanofi-Aventis and GlaxoSmithKline. Commenting Lebeaut said: “Yan is an outstanding biopharmaceutical executive who brings over 18 years of industry experience in oncology development across solid tumors, hematology‐oncology, gene and immune‐therapy. In his new role, Yan will lead and further strengthen our global oncology development powerhouse.”

Meanwhile McEwan, the author of more than 900 articles in peer reviewed journals and past President of the Society of Nuclear Medicine and Molecular Imaging, joins the organisation from the University of Alberta in which he held positions as Professor in the Department of Oncology and Adjunct Professor for the Department of Radiology and Diagnostic Imaging.

Lebeaut noted: “Sandy is a world-renowned expert in oncology and nuclear medicine who brings to Ipsen unique experience in this field. He will play a defining role in the acceleration of the development of Ipsen’s radiotherapeutics pipeline, providing strategic direction and managing the execution of the global clinical development of both satoreotide tetraxetan (IPN01072) and Satoreotide Trizoxetan (IPN01070) and also IPN01087 programs. Sandy will build and maintain trustworthy relationships with external oncology and nuclear medicine experts, academic networks, and professional organizations.”

SOURCE: www.pharmafile.com/appointment/518915